<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A calcineurin inhibitor combined with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> is the standard prophylaxis for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Everolimus, a derivative of <z:chebi fb="0" ids="9168">sirolimus</z:chebi>, seems to mediate antileukemia effects </plain></SENT>
<SENT sid="2" pm="."><plain>We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 17) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted, and only 1 patient experienced grade IV mucositis </plain></SENT>
<SENT sid="4" pm="."><plain>Nine patients (37%) developed <z:hpo ids='HP_0011009'>acute</z:hpo> grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed <z:hpo ids='HP_0011010'>chronic</z:hpo> extensive GVHD </plain></SENT>
<SENT sid="5" pm="."><plain>Transplantation-associated <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> (<z:chebi fb="39" ids="18139,53050">TMA</z:chebi>) occurred in 7 patients (29%), with 2 cases of <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The study was terminated prematurely because an additional 6 patients (25%) developed <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> (SOS), which was fatal in 2 cases </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 26 months, the 2-year overall survival rate was 47% </plain></SENT>
<SENT sid="8" pm="."><plain>Although this new combination appears to be effective as a prophylactic regimen for <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, the incidence of <z:chebi fb="39" ids="18139,53050">TMA</z:chebi> and SOS is considerably higher than seen with other regimens </plain></SENT>
</text></document>